Hang Quach

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/4691929/publications.pdf

Version: 2024-02-01

140 papers	6,303 citations	201674 27 h-index	74163 75 g-index
140 all docs	140 docs citations	140 times ranked	6308 citing authors

#	Article	IF	Citations
1	Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia. New England Journal of Medicine, 2015, 373, 2425-2437.	27.0	1,261
2	Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma. New England Journal of Medicine, 2019, 380, 2104-2115.	27.0	684
3	Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study. Lancet Oncology, The, 2020, 21, 207-221.	10.7	544
4	Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial. Lancet, The, 2019, 393, 229-240.	13.7	517
5	Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): results from a randomised, multicentre, open-label, phase 3 study. Lancet, The, 2020, 396, 186-197.	13.7	299
6	Daratumumab plus bortezomib and dexamethasone versus bortezomib and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of CASTOR. Haematologica, 2018, 103, 2079-2087.	3.5	225
7	Once-per-week selinexor, bortezomib, and dexamethasone versus twice-per-week bortezomib and dexamethasone in patients with multiple myeloma (BOSTON): a randomised, open-label, phase 3 trial. Lancet, The, 2020, 396, 1563-1573.	13.7	188
8	Isatuximab, carfilzomib, and dexamethasone in relapsed multiple myeloma (IKEMA): a multicentre, open-label, randomised phase 3 trial. Lancet, The, 2021, 397, 2361-2371.	13.7	177
9	T-cell acute leukaemia exhibits dynamic interactions with bone marrow microenvironments. Nature, 2016, 538, 518-522.	27.8	159
10	The immunostimulatory effect of lenalidomide on NK-cell function is profoundly inhibited by concurrent dexamethasone therapy. Blood, 2011, 117, 1605-1613.	1.4	152
11	Daratumumab, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone alone in newly diagnosed multiple myeloma (MAIA): overall survival results from a randomised, open-label, phase 3 trial. Lancet Oncology, The, 2021, 22, 1582-1596.	10.7	141
12	Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group. Lancet Oncology, The, 2021, 22, e105-e118.	10.7	136
13	A phase 2, multicentre, single-arm, open-label study to evaluate the safety and efficacy of single-agent lenalidomide (RevlimidÂ®) in subjects with relapsed or refractory peripheral T-cell non-Hodgkin lymphoma: The EXPECT trial. European Journal of Cancer, 2013, 49, 2869-2876.	2.8	114
14	Prognostic value of end-of-induction PET response after first-line immunochemotherapy for follicular lymphoma (GALLIUM): secondary analysis of a randomised, phase 3 trial. Lancet Oncology, The, 2018, 19, 1530-1542.	10.7	91
15	A high rate of durable responses with romidepsin, bortezomib, and dexamethasone in relapsed or refractory multiple myeloma. Blood, 2011, 118, 6274-6283.	1.4	83
16	Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): updated outcomes from a randomised, multicentre, open-label, phase 3 study. Lancet Oncology, The, 2022, 23, 65-76.	10.7	80
17	Enumeration, functional responses and cytotoxic capacity of MAIT cells in newly diagnosed and relapsed multiple myeloma. Scientific Reports, 2018, 8, 4159.	3.3	79
18	Sustained minimal residual disease negativity in newly diagnosed multiple myeloma and the impact of daratumumab in MAIA and ALCYONE. Blood, 2022, 139, 492-501.	1.4	64

#	Article	IF	Citations
19	Ixazomib as Postinduction Maintenance for Patients With Newly Diagnosed Multiple Myeloma Not Undergoing Autologous Stem Cell Transplantation: The Phase III TOURMALINE-MM4 Trial. Journal of Clinical Oncology, 2020, 38, 4030-4041.	1.6	56
20	Phase I Study of Venetoclax Plus Daratumumab and Dexamethasone, With or Without Bortezomib, in Patients With Relapsed or Refractory Multiple Myeloma With and Without t(11;14). Journal of Clinical Oncology, 2021, 39, 3602-3612.	1.6	44
21	Daratumumab plus lenalidomide and dexamethasone in transplant-ineligible newly diagnosed multiple myeloma: frailty subgroup analysis of MAIA. Leukemia, 2022, 36, 1066-1077.	7.2	39
22	In Vivo Tracking of Dendritic Cells in Patients With Multiple Myeloma. Journal of Immunotherapy, 2008, 31, 166-179.	2.4	38
23	Australian and New Zealand consensus statement on the management of lymphoma, chronic lymphocytic leukaemia and myeloma during the <scp>COVID</scp>â€19 pandemic. Internal Medicine Journal, 2020, 50, 667-679.	0.8	37
24	Zanubrutinib (BGB-3111) plus obinutuzumab in patients with chronic lymphocytic leukemia and follicular lymphoma. Blood Advances, 2020, 4, 4802-4811.	5.2	33
25	Daratumumab, bortezomib, and dexamethasone in relapsed or refractory multiple myeloma: subgroup analysis of CASTOR based on cytogenetic risk. Journal of Hematology and Oncology, 2020, 13, 115.	17.0	32
26	DREAMM-6: Safety and tolerability of belantamab mafodotin in combination with bortezomib/dexamethasone in relapsed/refractory multiple myeloma (RRMM).. Journal of Clinical Oncology, 2020, 38, 8502-8502.	1.6	32
27	Considerations for preâ€transfusion immunohaematology testing in patients receiving the antiâ€CD38 monoclonal antibody daratumumab for the treatment of multiple myeloma. Internal Medicine Journal, 2018, 48, 210-220.	0.8	31
28	Phase 3 Randomized Study of Daratumumab Plus Lenalidomide and Dexamethasone (D-Rd) Versus Lenalidomide and Dexamethasone (Rd) in Patients with Newly Diagnosed Multiple Myeloma (NDMM) Ineligible for Transplant (MAIA). Blood, 2018, 132, LBA-2-LBA-2.	1.4	30
29	Failure of eculizumab to correct paroxysmal cold hemoglobinuria. Annals of Hematology, 2011, 90, 989-990.	1.8	27
30	Carfilzomib, Dexamethasone, and Daratumumab Versus Carfilzomib and Dexamethasone for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma (RRMM): Primary Analysis Results from the Randomized, Open-Label, Phase 3 Study Candor (NCT03158688). Blood, 2019, 134, LBA-6-LBA-6.	1.4	27
31	DREAMM-6: Safety, Tolerability and Clinical Activity of Belantamab Mafodotin (Belamaf) in Combination with Bortezomib/Dexamethasone (BorDex) in Relapsed/Refractory Multiple Myeloma (RRMM). Blood, 2020, 136, 19-20.	1.4	27
32	Daratumumab Plus Lenalidomide and Dexamethasone (D-Rd) Versus Lenalidomide and Dexamethasone (Rd) in Patients with Newly Diagnosed Multiple Myeloma (NDMM) Ineligible for Transplant: Updated Analysis of Maia. Blood, 2019, 134, 1875-1875.	1.4	26
33	Lenalidomide in multiple myeloma: Current status and future potential. American Journal of Hematology, 2012, 87, 1089-1095.	4.1	25
34	Design and development of the Australian and New Zealand (ANZ) myeloma and related diseases registry. BMC Medical Research Methodology, 2016, 16, 151.	3.1	25
35	Singleâ€agent ibrutinib versus chemoimmunotherapy regimens for treatmentâ€naÃ¯ve patients with chronic lymphocytic leukemia: A crossâ€trial comparison of phase 3 studies. American Journal of Hematology, 2018, 93, 1402-1410.	4.1	24
36	Secondary clonal cytogenetic abnormalities following successful treatment of acute promyelocytic leukemia. American Journal of Hematology, 2009, 84, 715-719.	4.1	23

#	Article	IF	Citations
37	Thrombotic microangiopathy complicating bortezomib-based therapy for multiple myeloma. Leukemia and Lymphoma, 2015, 56, 2185-2186.	1.3	23
38	Belantamab mafodotin in combination with novel agents in relapsed/refractory multiple myeloma: DREAMM-5 study design. Future Oncology, 2021, 17, 1987-2003.	2.4	23
39	Spontaneous onset and transplant models of the Vk*MYC mouse show immunological sequelae comparable to human multiple myeloma. Journal of Translational Medicine, 2016, 14, 259.	4.4	21
40	Upfront lower dose lenalidomide is less toxic and does not compromise efficacy for vulnerable patients with relapsed refractory multiple myeloma: final analysis of the phase II RevLite study. British Journal of Haematology, 2017, 177, 441-448.	2.5	21
41	Pharmacokinetics and safety of carfilzomib in patients with relapsed multiple myeloma and end-stage renal disease (ESRD): an open-label, single-arm, phase I study. Cancer Chemotherapy and Pharmacology, 2017, 79, 1067-1076.	2.3	21
42	Bisphosphonate guidelines for treatment and prevention of myeloma bone disease. Internal Medicine Journal, 2017, 47, 938-951.	0.8	19
43	Regulatory T Cells (Treg) Are Depressed in Patients with Relapsed/Refractory Multiple Myeloma (MM) and Increases towards Normal Range in Responding Patients Treated with Lenalidomide (LEN).. Blood, 2008, 112, 1696-1696.	1.4	19
44	Efficacy of daratumumab in combination with lenalidomide plus dexamethasone (DRd) or bortezomib plus dexamethasone (DVd) in relapsed or refractory multiple myeloma (RRMM) based on cytogenetic risk status.. Journal of Clinical Oncology, 2017, 35, 8006-8006.	1.6	18
45	Epidemiology and Risks of Infections in Patients With Multiple Myeloma Managed With New Generation Therapies. Clinical Lymphoma, Myeloma and Leukemia, 2021, 21, 444-450.e3.	0.4	17
46	Conventional Treatment for Multiple Myeloma Drives Premature Aging Phenotypes and Metabolic Dysfunction in T Cells. Frontiers in Immunology, 2020, 11, 2153.	4.8	16
47	Effect of age and frailty on the efficacy and tolerability of onceâ€weekly selinexor, bortezomib, and dexamethasone in previously treated multiple myeloma. American Journal of Hematology, 2021, 96, 708-718.	4.1	16
48	Selinexor, bortezomib, and dexamethasone versus bortezomib and dexamethasone in previously treated multiple myeloma: Outcomes by cytogenetic risk. American Journal of Hematology, 2021, 96, 1120-1130.	4.1	15
49	Nilotinib doseâ€optimization in newly diagnosed chronic myeloid leukaemia in chronic phase: final results from <scp>ENEST</scp>xtnd. British Journal of Haematology, 2017, 179, 219-228.	2.5	14
50	Oral ixazomib-dexamethasone vs oral pomalidomide-dexamethasone for lenalidomide-refractory, proteasome inhibitor-exposed multiple myeloma: a randomized Phaseï»¿ 2 trial. Blood Cancer Journal, 2022, 12, 9.	6.2	14
51	Pembrolizumab plus dinaciclib in patients with hematologic malignancies: the phase 1b KEYNOTE-155 study. Blood Advances, 2022, 6, 1232-1242.	5.2	14
52	Initial safety results for MagnetisMM-3: A phase 2 trial of elranatamab, a B-cell maturation antigen (BCMA)-CD3 bispecific antibody, in patients (pts) with relapsed/refractory (R/R) multiple myeloma (MM).. Journal of Clinical Oncology, 2022, 40, 8006-8006.	1.6	14
53	Drug-mediated and cellular immunotherapy in multiple myeloma. Immunotherapy, 2010, 2, 243-255.	2.0	13
54	Treatment of patients with multiple myeloma who are eligible for stem cell transplantation: position statement of the <scp>M</scp>yeloma <scp>F</scp>oundation of <scp>A</scp>ustralia <scp>M</scp>edical and <scp>S</scp>cientific <scp>A</scp>dvisory <scp>G</scp>roup. Internal Medicine Journal, 2015, 45, 94-105.	0.8	13

#	Article	IF	Citations
55	Renal Impairment at Diagnosis in Myeloma: Patient Characteristics, Treatment, and Impact on Outcomes. Results From the Australia and New Zealand Myeloma and Related Diseases Registry. Clinical Lymphoma, Myeloma and Leukemia, 2019, 19, e415-e424.	0.4	13
56	DREAMM-9: Phase III study of belantamab mafodotin plus VRd versus VRd alone in transplant-ineligible newly diagnosed multiple myeloma (TI NDMM).. Journal of Clinical Oncology, 2020, 38, TPS8556-TPS8556.	1.6	13
57	<scp>COVID</scp>â€19 vaccination in haematology patients: an Australian and New Zealand consensus position statement. Internal Medicine Journal, 2021, 51, 763-768.	0.8	12
58	The Myeloma Landscape in Australia and New Zealand: The First 8 Years of the Myeloma and Related Diseases Registry (MRDR). Clinical Lymphoma, Myeloma and Leukemia, 2021, 21, e510-e520.	0.4	12
59	â€˜Real-worldâ€™ Australian experience of pomalidomide for relapsed and refractory myeloma. Leukemia and Lymphoma, 2018, 59, 1514-1516.	1.3	11
60	Glucose-regulated protein 78 (GRP78) as a potential novel biomarker and therapeutic target in multiple myeloma. Expert Review of Hematology, 2020, 13, 1201-1210.	2.2	11
61	Effect of prior treatments on selinexor, bortezomib, and dexamethasone in previously treated multiple myeloma. Journal of Hematology and Oncology, 2021, 14, 59.	17.0	11
62	Real-World Outcome for Newly Diagnosed Patients with Functional High-Risk Myeloma - a Myeloma and Related Diseases Registry Analysis. Blood, 2019, 134, 269-269.	1.4	11
63	Updated analysis of a phase I/II study of venetoclax in combination with daratumumab and dexamethasone, +/- bortezomib, in patients with relapsed/refractory multiple myeloma.. Journal of Clinical Oncology, 2020, 38, 8511-8511.	1.6	11
64	ASTCT Clinical Practice Recommendations for Transplantation and Cellular Therapies in Multiple Myeloma. Transplantation and Cellular Therapy, 2022, 28, 284-293.	1.2	11
65	Synergistic effects of low-dose belantamab mafodotin in combination with a gamma-secretase inhibitor (nirogacestat) in patients with relapsed/refractory multiple myeloma (RRMM): DREAMM-5 study.. Journal of Clinical Oncology, 2022, 40, 8019-8019.	1.6	11
66	Treatment of patients with WaldenstrÃ¶m macroglobulinaemia: clinical practice guidelines from the Myeloma Foundation of Australia Medical and Scientific Advisory Group. Internal Medicine Journal, 2017, 47, 35-49.	0.8	10
67	Efficacy of Daratumumab in Combination with Standard of Care Regimens in Lenalidomide-Exposed or -Refractory Patients with Relapsed/Refractory Multiple Myeloma (RRMM): Analysis of the Castor, Pollux, and MMY1001 Studies. Blood, 2018, 132, 3288-3288.	1.4	10
68	Lower-Dose Lenalidomide and Dexamethasone Reduces Toxicity without Compromising Efficacy In Patients with Relapsed/Refractory Myeloma, Who Are Aged â‰¥60 Years or Have Renal Impairment: Planned Interim Results of a Prospective Multicentre Phase II Trial. Blood, 2010, 116, 1961-1961.	1.4	10
69	Predicting durable remissions following thalidomide therapy for relapsed myeloma. Leukemia and Lymphoma, 2009, 50, 223-229.	1.3	9
70	Health-related quality of life in the phase III GALLIUM study of obinutuzumab- or rituximab-based chemotherapy in patients with previously untreated advanced follicular lymphoma. Annals of Hematology, 2020, 99, 2837-2846.	1.8	9
71	Safety and Efficacy of the Combination of Bortezomib with the Deacetylase Inhibitor Romidepsin in Patients with Relapsed or Refractory Multiple Myeloma: Preliminary Results of a Phase I Trial.. Blood, 2007, 110, 1167-1167.	1.4	9
72	Successful use of eltrombopag without splenectomy in refractory HIV-related immune reconstitution thrombocytopenia. Aids, 2012, 26, 1977-1979.	2.2	8

#	Article	IF	Citations
73	Cytarabine-based induction immunochemotherapy in the front-line treatment of older patients with mantle cell lymphoma. Scientific Reports, 2019, 9, 13544.	3.3	8
74	Myeloma natural killer cells are exhausted and have impaired regulation of activation. Haematologica, 2021, 106, 2522-2526.	3.5	8
75	CD57+ NK CELLS ARE Increased In Patients With Multiple Myeloma and ARE Primed Effectors For ADCC, But NOT Natural Cytotoxicty. Blood, 2013, 122, 1904-1904.	1.4	8
76	Predictors of early mortality in multiple myeloma: Results from the Australian and New Zealand Myeloma and Related Diseases Registry (<scp>MRDR</scp>). British Journal of Haematology, 2022, 198, 830-837.	2.5	8
77	The addition of dexamethasone to bortezomib for patients with relapsed multiple myeloma improves outcome but ongoing maintenance therapy has minimal benefit. American Journal of Hematology, 2015, 90, E86-91.	4.1	7
78	Real-world utilisation of ASCT in multiple myeloma (MM): a report from the Australian and New Zealand myeloma and related diseases registry (MRDR). Bone Marrow Transplantation, 2021, 56, 2533-2543.	2.4	7
79	Carfilzomib, dexamethasone and daratumumab in relapsed or refractory multiple myeloma: results of the phase III study CANDOR by prior lines of therapy. British Journal of Haematology, 2021, 194, 784-788.	2.5	7
80	Peripheral neuropathy symptoms, pain, and functioning in previously treated multiple myeloma patients treated with selinexor, bortezomib, and dexamethasone. American Journal of Hematology, 2021, 96, E383-E386.	4.1	7
81	Efficacy and tolerability of <scp>onceâ€weekly</scp> selinexor, bortezomib, and dexamethasone in comparison with standard <scp>twiceâ€weekly</scp> bortezomib and dexamethasone in previously treated multiple myeloma with renal impairment: Subgroup analysis from the <scp>BOSTON</scp> study. American Journal of Hematology, 2022, 97, .	4.1	7
82	Safety and clinical activity of belantamab mafodotin with lenalidomide plus dexamethasone in patients with relapsed/refractory multiple myeloma (RRMM): DREAMM-6 arm-A interim analysis.. Journal of Clinical Oncology, 2022, 40, 8017-8017.	1.6	7
83	Managing multiple myeloma in the elderly: are we making progress?. Expert Review of Hematology, 2011, 4, 301-315.	2.2	6
84	Treatment of patients with multiple myeloma who are not eligible for stem cell transplantation: position statement of the myeloma foundation of <scp>A</scp>ustralia <scp>M</scp>edical and <scp>S</scp>cientific <scp>A</scp>dvisory <scp>G</scp>roup. Internal Medicine Journal, 2015, 45, 335-343.	0.8	6
85	Shaping the Treatment Paradigm Based on the Current Understanding of the Pathobiology of Multiple Myeloma: An Overview. Cancers, 2020, 12, 3488.	3.7	6
86	Patientâ€reported outcome measures in multiple myeloma: Realâ€time reporting to improve care (<scp>Myâ€PROMPT</scp>) â€•a pilot randomized controlled trial. American Journal of Hematology, 2020, 95, E178-E181.	4.1	6
87	Clinical Outcomes in Patients (Pts) with Dose Reduction of Selinexor in Combination with Bortezomib, and Dexamethasone (XVd) in Previously Treated Multiple Myeloma from the Boston Study. Blood, 2021, 138, 3793-3793.	1.4	6
88	Perspectives in the Rapidly Evolving Treatment Landscape of Multiple Myeloma: Expert Review of New Data Presentations from ASH 2019. Clinical Lymphoma, Myeloma and Leukemia, 2020, 20, 724-735.	0.4	5
89	Excellent outcomes in older patients with primary CNS lymphoma treated with R-MPV/cytarabine without whole brain radiotherapy or autologous stem cell transplantation therapy. Leukemia and Lymphoma, 2021, 62, 112-117.	1.3	5
90	Pralatrexate in relapsed/refractory T-cell lymphoma: a retrospective multicenter study. Leukemia and Lymphoma, 2021, 62, 330-336.	1.3	5

#	Article	IF	Citations
91	Low rates of invasive fungal disease in patients with multiple myeloma managed with new generation therapies: Results from a multiâ€centre cohort study. Mycoses, 2021, 64, 30-34.	4.0	5
92	A phase 1b dose-escalation/expansion study of BET inhibitor RO6870810 in patients with advanced multiple myeloma. Blood Cancer Journal, 2021, 11, 149.	6.2	5
93	Daratumumab, Bortezomib and Dexamethasone Versus Bortezomib and Dexamethasone Alone for Relapsed or Refractory Multiple Myeloma Based on Prior Treatment Exposure: Updated Efficacy Analysis of Castor. Blood, 2016, 128, 3313-3313.	1.4	5
94	Ixazomib vs placebo maintenance for newly diagnosed multiple myeloma (NDMM) patients not undergoing autologous stem cell transplant (ASCT): The phase III TOURMALINE-MM4 trial.. Journal of Clinical Oncology, 2020, 38, 8527-8527.	1.6	5
95	MRD end point in myeloma: ready for prime time?. Blood, 2022, 139, 799-802.	1.4	5
96	Treatment Strategies in Elderly Patients with Multiple Myeloma. Drugs and Aging, 2007, 24, 829-850.	2.7	4
97	Extra-nasal NK/T cell lymphoma masquerading as renal infarction. Leukemia and Lymphoma, 2010, 51, 1139-1141.	1.3	4
98	Reversal of Transfusion Dependence by Tumor Necrosis Factor Inhibitor Treatment in a Patient With Concurrent Rheumatoid Arthritis and Primary Myelofibrosis. Journal of Clinical Rheumatology, 2011, 17, 211-213.	0.9	4
99	Response: dexamethasone dose alters expression of NK activating receptors in vivo. Blood, 2011, 118, 6466-6468.	1.4	4
100	Comment on "Retrospective matched-pairs analysis of bortezomib plus dexamethasone versus bortezomib monotherapy in relapsed multiple myeloma". Haematologica, 2015, 100, e379-e379.	3.5	4
101	Daratumumab, bortezomib and dexamethasone (DVd) vs bortezomib and dexamethasone (Vd) in relapsed or refractory multiple myeloma (RRMM): Efficacy and safety update (CASTOR).. Journal of Clinical Oncology, 2017, 35, 8036-8036.	1.6	4
102	Impact of age on efficacy and safety of daratumumab in combination with lenalidomide and dexamethasone (D-Rd) in patients (pts) with transplant-ineligible newly diagnosed multiple myeloma (NDMM): MAIA.. Journal of Clinical Oncology, 2019, 37, 8035-8035.	1.6	4
103	Phase I/II, open-label, 2-arm study to evaluate safety, tolerability, and clinical activity of GSK2857916 in combination with 2 standard-of-care (SoC) regimens in relapsed/refractory multiple myeloma: (DREAMM 6).. Journal of Clinical Oncology, 2019, 37, TPS8053-TPS8053.	1.6	4
104	Whole Brain Radiotherapy and Ara-C In Consolidation Post High-Dose Methotrexate Is Important In Establishing Durable Disease Control In the Treatment of Primary CNS Lymphoma: A Single Centre Observational Study. Blood, 2010, 116, 1776-1776.	1.4	4
105	Genomic Predictors of Progression-Free Survival Among Patients with Relapsed or Refractory Multiple Myeloma Treated with Carfilzomib and Dexamethasone or Bortezomib and Dexamethasone in the Phase 3 Endeavor Trial. Blood, 2017, 130, 839-839.	1.4	4
106	Depth of response and response kinetics of isatuximab plus carfilzomib and dexamethasone in relapsed multiple myeloma. Blood Advances, 2022, 6, 4506-4515.	5.2	4
107	Subcutaneous (SC) isatuximab administration by an on-body delivery system (OBDS) in combination with pomalidomide-dexamethasone (Pd) in patients with relapsed/refractory multiple myeloma (RRMM): Interim phase 1b study results.. Journal of Clinical Oncology, 2022, 40, 8025-8025.	1.6	4
108	Myeloma of the central nervous system â€“ an ongoing conundrum!. Leukemia and Lymphoma, 2016, 57, 1505-1506.	1.3	3

#	Article	IF	Citations
109	A randomized, open-label, phase 3 study of low-dose selinexor and lenalidomide (Len) versus len maintenance post autologous stem cell transplant (ASCT) for newly diagnosed multiple myeloma (NDMM): ALLG MM23, Sealand.. Journal of Clinical Oncology, 2021, 39, TPS8055-TPS8055.	1.6	3
110	Successful identification of predictive profiles for infection utilising systemsâ€level immune analysis: a pilot study in patients with relapsed and refractory multiple myeloma. Clinical and Translational Immunology, 2021, 10, e1235.	3.8	3
111	Survival among older patients with previously treated multiple myeloma treated with selinexor, bortezomib, and dexamethasone (XVd) in the BOSTON study.. Journal of Clinical Oncology, 2021, 39, 8019-8019.	1.6	2
112	Receiving four or fewer cycles of therapy predicts poor survival in newly diagnosed transplantâ€ineligible patients with myeloma who are treated with bortezomibâ€based induction. European Journal of Haematology, 2021, 107, 497-499.	2.2	2
113	Cardiac Safety of One Versus Four Hour Romidepsin (IstodaxÂ®) Infusion In the Setting of a Phase I/II Trial of Romidepsin, Dexamethasone and Bortezomib for Relapsed or Refractory Multiple Myeloma. Blood, 2010, 116, 5037-5037.	1.4	2
114	Dose-Optimized Nilotinib (NIL) in Patients (Pts) with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP): Final Results from ENESTxtnd Study. Blood, 2015, 126, 344-344.	1.4	2
115	High GRP78 (78-kDa Glucose-Regulated Protein) Expression Predicts for a Favorable Clinical Outcome in Patients with Multiple Myeloma and May be a Potentially Useful Therapeutic Target in the Treatment of Multiple Myeloma. Blood, 2015, 126, 4206-4206.	1.4	2
116	Lower Dose Lenalidomide and Dexamethasone for Patients with Relapsed/Refractory Multiple Myeloma Who Are Aged 60 Years or over and/or at Risk of Myelosuppression: Final Analysis of the Revlite Trial and Matched Comparison to the MM009 and MM010 Trials. Blood, 2015, 126, 4236-4236.	1.4	2
117	Results from the International, Randomized Phase 3 Study of Ibrutinib Versus Chlorambucil in Patients 65 Years and Older with Treatment-NaÃ¯ve CLL/SLL (RESONATE-2TM). Blood, 2015, 126, 495-495.	1.4	2
118	Dreamm-5 Platform Trial: Belantamab Mafodotin (Belamaf) in Combination with Four Different Novel Agents in Patients with Relapsed/Refractory Multiple Myeloma (RRMM). Blood, 2020, 136, 1-2.	1.4	2
119	Cell surface glucose-regulated protein 78 (GRP78) is upregulated in plasma cells of patients with multiple myeloma compared to monoclonal gammopathy of uncertain significance. Clinical Lymphoma, Myeloma and Leukemia, 2019, 19, e95-e96.	0.4	1
120	Higher Intensity of Cell Surface Glucose-Regulated Protein 78 (csGRP78) Expression Is Seen in Patients with Early Progressive Disease/Mortality in a Cohort of Relapsed, Refractory Multiple Myeloma Patients Treated with Carfilzomib, Thalidomide and Dexamethasone. Blood, 2019, 134, 4376-4376.	1.4	1
121	Sustained Minimal Residual Disease (MRD) Negativity and Clinical Efficacy in Transplant-Ineligible (TIE) Newly Diagnosed Multiple Myeloma (NDMM) Patients (Pts) Treated with Daratumumab-Based Regimens: Analysis of Maia and Alcyone. Blood, 2020, 136, 18-20.	1.4	1
122	A 2-Stage Phase II Study of Panobinostat Consolidation in Multiple Myeloma (MM) Patients with < CR Following Single High-Dose Chemotherapy (HDT) Conditioned Autologous Stem Cell Transplantation (ASCT) As Part of First Line Therapy. Blood, 2016, 128, 4515-4515.	1.4	1
123	Efficacy and safety of daratumumab, bortezomib, and dexamethasone (D-Vd) in relapsed or refractory multiple myeloma (RRMM) based on cytogenetic risk: Updated subgroup analysis of CASTOR.. Journal of Clinical Oncology, 2019, 37, 8040-8040.	1.6	1
124	Imaging of patients with multiple myeloma and associated plasma cell disorders: consensus practice statement by the Medical Scientific Advisory Group to Myeloma Australia. Internal Medicine Journal, 2021, 51, 1707-1712.	0.8	1
125	Intravital Microscopy Reveals Fundamental Differences in the Interaction of Stem Cells and T Acute Lymphoblastic Leukaemia with the Bone Marrow Microenvironment. Blood, 2016, 128, 5199-5199.	1.4	1
126	Response Adaptive Salvage Treatment with Carfilzomib-Thalidomide-Dexamethasone for Newly Diagnosed Transplant Eligible Multiple Myeloma Patients Failing Front-Line Bortezomib-Based Induction Therapy - Final Analysis from the Australasian Leukemia and Lymphoma Group (ALLG) MM17 Trial. Blood, 2021, 138, 1663-1663.	1.4	1

#	Article	IF	Citations
127	Isatuximab Rescue for Inadequate Response to Lenalidomide and Dexamethasone in Transplant Ineligible Patients with Newly Diagnosed Multiple Myeloma: Interim Analysis of the Phase II Iril Study of the Australian Myeloma Research Consortium (AMaRC 18-02). Blood, 2021, 138, 1671-1671.	1.4	1
128	A Randomized Study of Bortezomib, Cyclophosphamide and Dexamethasone Induction (VCD) Versus VCD and Daratumumab Induction Followed By Daratumumab Maintenance (VCDD) for the Initial Treatment of Transplant-Ineligible Patients with Multiple Myeloma (AMaRC 03-16). Blood, 2021, 138, 2728-2728.	1.4	1
129	Effects of Cytogenetic Risk on Outcomes in Multiple Myeloma Treated with Selinexor, Bortezomib, and Dexamethasone (XVd). Blood, 2021, 138, 1634-1634.	1.4	1
130	Efficacy of Daratumumab, Lenalidomide, and Dexamethasone in Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma and Impaired Renal Function from the Phase 3 Maia Study Based on Lenalidomide Starting Dose. Blood, 2021, 138, 1646-1646.	1.4	1
131	CAMMA 3: A multicenter phase Ib trial evaluating the safety, pharmacokinetics, and activity of subcutaneous cevostamab monotherapy in patients with relapsed or refractory multiple myeloma.. Journal of Clinical Oncology, 2022, 40, TPS8070-TPS8070.	1.6	1
132	Serum protein electrophoresis: a precautionary tale. Pathology, 2012, 44, 371-373.	0.6	0
133	Radiotherapy in orbital lymphoma: optimizing the backbone to build upon. Leukemia and Lymphoma, 2013, 54, 445-446.	1.3	0
134	Planned withdrawal of dexamethasone after pomalidomide low dose dexamethasone induction for lenalidomide refractory multiple myeloma (ALLG MM14). Haematologica, 2021, , .	3.5	0
135	Preliminary Analysis of the Australasian Leukaemia and Lymphoma Group (ALLG) MM17 Trial: Response Adaptive Salvage Treatment with Carfilzomib-Thalidomide-Dexamethasone (KTd) for Newly Diagnosed Transplant Eligible Multiple Myeloma Patients Failing Front-Line Bortezomib-Based Induction Therapy. Blood, 2018, 132, 3279-3279.	1.4	0
136	Characterization of Cardiovascular Adverse Events and B-Type Natriuretic Peptide Levels in Patients with Multiple Myeloma Who Are Treated with Carfilzomib. Blood, 2018, 132, 1956-1956.	1.4	0
137	Assessing the Immune Tumour Microenvironment (iTME) Using Multiplex Immunoflourescence Histochemistry (mIHC) Demonstrates Close Proximity of Cytotoxic T-Cells to Plasma Cells (PC) in Patients with Newly Diagnosed Multiple Myeloma (NDMM). Blood, 2021, 138, 4705-4705.	1.4	0
138	Preliminary Analysis of the MM21 Trial: Response Adaptive Salvage Treatment with Daratumumab-Lenalidomide-Dexamethasone (DRd) for Newly Diagnosed Transplant Eligible Multiple Myeloma Patients Failing Front-Line Bortezomib-Based Induction Therapy. Blood, 2021, 138, 1665-1665.	1.4	0
139	Meaningful Changes in Patient-Reported Outcomes in Relation to Best Clinical Response and Disease Progression: Post Hoc Analyses from MAIA. Blood, 2021, 138, 4095-4095.	1.4	0
140	Circulating tumor DNA analysis and association with relapse in patients with primary refractory multiple myeloma receiving secondary salvage therapy.. Journal of Clinical Oncology, 2022, 40, 8037-8037.	1.6	0